| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Xiang-Peng Kong | Q41629080 |
| P2093 | author name string | Susan Zolla-Pazner | |
| Raymond Alvarez | |||
| Svenja Weiss | |||
| P2860 | cites work | HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells | Q22251066 |
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Q27675879 | ||
| Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals | Q27677941 | ||
| Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops | Q27678226 | ||
| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time | Q29547822 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel | Q30152923 | ||
| Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial | Q30532861 | ||
| A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure | Q33592001 | ||
| Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge | Q33804531 | ||
| Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. | Q33809112 | ||
| Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection | Q33834852 | ||
| Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology | Q33851717 | ||
| V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. | Q33874253 | ||
| HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. | Q33887674 | ||
| HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities | Q33900395 | ||
| Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques | Q33966586 | ||
| Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination | Q33977866 | ||
| Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines | Q34057711 | ||
| Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer | Q34292319 | ||
| Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 | Q34292765 | ||
| Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 | Q34298408 | ||
| The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection | Q34317025 | ||
| Activation of complement on the surface of cells infected by human immunodeficiency virus | Q41744013 | ||
| Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. | Q41924059 | ||
| Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines | Q42230293 | ||
| Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope | Q46331384 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| Non-Neutralizing Antibodies Directed against HIV and Their Functions | Q47139556 | ||
| Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. | Q47215816 | ||
| HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees | Q47547483 | ||
| Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. | Q47555452 | ||
| Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges. | Q51743315 | ||
| High-resolution definition of humoral immune response correlates of effective immunity against HIV. | Q55022148 | ||
| Analysis of complement-mediated lysis of SIV and SIV-infected cells reveals sex differences in vaccine-induced immune responses in Rhesus macaques | Q56517281 | ||
| Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques | Q56517308 | ||
| Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion | Q57283084 | ||
| Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7 | Q57751823 | ||
| Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions | Q58115616 | ||
| V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity | Q60959639 | ||
| Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
| Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV | Q91276841 | ||
| Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial | Q34374835 | ||
| Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection | Q34402934 | ||
| Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles | Q34406977 | ||
| Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. | Q34540352 | ||
| Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial | Q34562259 | ||
| Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody | Q34630446 | ||
| Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. | Q34907398 | ||
| Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions | Q35006601 | ||
| Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia | Q35105449 | ||
| Structure and immune recognition of trimeric pre-fusion HIV-1 Env. | Q35142291 | ||
| Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection | Q35363127 | ||
| Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function | Q35600028 | ||
| Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys | Q35729899 | ||
| Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor | Q35857404 | ||
| Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control | Q35888710 | ||
| Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein | Q36294806 | ||
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | Q36363231 | ||
| Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis | Q36795915 | ||
| Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees | Q36978671 | ||
| Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques | Q37033311 | ||
| Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies | Q37184296 | ||
| Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. | Q37347813 | ||
| Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys | Q37355237 | ||
| Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits | Q37448281 | ||
| Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. | Q37625296 | ||
| Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. | Q37646897 | ||
| Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner | Q38719420 | ||
| Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer. | Q38725480 | ||
| Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. | Q39357299 | ||
| Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate | Q39484956 | ||
| Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition | Q39726192 | ||
| Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins | Q39845715 | ||
| Protection against HIV Acquisition in the RV144 Trial | Q40137608 | ||
| Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells | Q40274328 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P433 | issue | 4 | |
| P921 | main subject | HIV vaccine | Q1479804 |
| human immunodeficiency virus infectious disease | Q18556697 | ||
| RNA virus infectious disease | Q18967413 | ||
| simian acquired immunodeficiency syndrome | Q19000697 | ||
| P304 | page(s) | 309-317 | |
| P577 | publication date | 2019-07-01 | |
| P1433 | published in | Current Opinion in HIV and AIDS | Q15724409 |
| P1476 | title | Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV | |
| P478 | volume | 14 |
| Q93038056 | HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions |
| Q92689689 | Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial |
| Q92538999 | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
| Q92478519 | V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers |
Search more.